Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29414460 | 0.85 | SMN1; SMN2 (0.49) | NPC1RAB9AMAPTALDH1A1HTT | |
| SCHEMBL29780593 | 0.85 | HRH4 (0.66) | NPC1RAB9AMAPTALDH1A1HTT | |
| SCHEMBL1442764 | 0.85 | SMN1; SMN2 (0.49) | NPC1RAB9AMAPTALDH1A1HTT | |
| SCHEMBL3088100 | 0.85 | HTT (0.51) | NPC1RAB9AMAPTALDH1A1HTT | |
| SCHEMBL2621746 | 0.85 | HRH4 (0.66) | NPC1RAB9AMAPTALDH1A1HTT | |
| SCHEMBL3094939 | 0.84 | NPC1 (0.42) | NPC1RAB9AMAPTALDH1A1HTT | |
| SCHEMBL12812383 | 0.81 | NPC1 (0.45) | L3MBTL1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL15141001 | 0.80 | HCAR2 (0.50) | NPC1RAB9AMAPTALDH1A1HTT | |
| SCHEMBL3095779 | 0.79 | HTT (0.43) | NPC1RAB9AMAPTALDH1A1HTT | |
| SCHEMBL21865079 | 0.79 | SMN1; SMN2 (0.49) | NPC1RAB9AMAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908866-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170283395-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9670180-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20150057277-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-02-26 | — | — | US | disclosed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| EP-2473498-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011026579-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057277-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | PDXK, DCK, CHEK1 | L3MBTL1 3710/4885NPC1 3627/4885RAB9A 2202/4885 |
| US-20170283395-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | PDXK, DCK, CHEK1 | L3MBTL1 3710/4885NPC1 3627/4885RAB9A 2202/4885 |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | ABL1, TYK2, JAK2 | L3MBTL1 1960/4885NPC1 4167/4885RAB9A 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.